榄香烯联合洛铂治疗肺癌性胸腔积液患者的疗效

doi:10.3969/j.issn.1671-7171.2026.01.020

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1141 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To investigate the clinical efficacy of elemene combined with lobaplatin in patients with malignant pleural effusion caused by lung cancer. 【Methods】 A total of 133 patients with lung cancer–related malignant pleural effusion were randomly divided into an observation group(n=66) and a control group(n=67). The control group received lobaplatin in addition to conventional treatment, while the observation group received lobaplatin combined with elemene. Clinical efficacy, as well as levels of cytokeratin 19 fragment antigen 21-1(CYFRA21-1), neuron-specific enolase(NSE), T-lymphocyte subsets, and inflammatory factors before and after treatment were compared between the two groups. 【Results】 The disease control rate in the observation group was 80.30%, which was significantly higher than 47.76% in the control group(P<0.05). After treatment, CYFRA21-1, NSE, CD8⁺, and inflammatory factor levels in the observation group were lower than those in the control group(P<0.05), while CD3⁺, CD4⁺, and CD4⁺/CD8⁺ levels in the observation group were higher than those in the control group(P<0.05). 【Conclusion】 Elemene combined with lobaplatin can effectively reduce CYFRA21-1 and NSE levels, modulate inflammatory factors and T-lymphocyte subsets, and improve clinical efficacy in patients with lung cancer-associated malignant pleural effusion.

Key words： Lung Neoplasms Pleural Effusion, Malignant Elemene Platinum Compounds

Received: 12 December 2024

PACS:

R734.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	GU Guomei

Cite this article:

GU Guomei. Efficacy of Elemene Combined with Lobaplatin in the Treatment of Malignant Pleural Effusion of Lung Cancer Patients[J]. JOURNAL OF CLINICAL RESEARCH, 2026, 43(1): 72-74.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2026.01.020 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2026/V43/I1/72

[1] 李锐成,千红维,范艳妮,等. Logistic回归和人工神经网络在鉴别诊断肺癌性胸腔积液中的应用研究[J].昆明医科大学学报,2024,45(10):55-60.
[2] LI T Y, TIAN P W, HUANG Q , et al.Development and validation of the CAIL prognostic score in non-small cell lung cancer patients with malignant pleural effusion[J].Clin Res J,2023,17(11):1158-1168.
[3] 吴慧杰,徐海英,张凌云,等. 榄香烯联合奈达铂腔内注射对恶性胸水患者效果观察及生存质量的影响[J].实用医学杂志,2021,37(14):1857-1860.
[4] 艾宁,李智岗,王永中,等. 雷替曲塞联合洛铂动脉灌注方案在原发性肝癌介入中的应用价值[J].河北医科大学学报,2019,40(12):1430-1432.
[5] 中华医学会肿瘤学分会,中华医学会杂志社. 中华医学会肿瘤学分会肺癌临床诊疗指南(2021版)[J].中华肿瘤杂志,2021,43(6):591-621.
[6] 周仲瑛.中医内科学[M].7版.北京:中国中医药出版社, 2003:408.
[7] 张萍,艾斌.实体瘤免疫治疗疗效评价标准[J].国际肿瘤学杂志,2016,43(11):848-851.
[8] KEIDAN N, AUJAYEB A. Small cell lung cancer and pleural effusion: an analysis from a district general hospital[J].Pulm Ther,2023, 9(3):359-365.
[9] 周江波,王东,马景鑑,等. 榄香烯联合血管内皮生长因子多克隆抗体对大鼠脑胶质瘤脑组织增殖细胞核抗原、组织金属蛋白酶抑制剂-1表达的影响[J].中华实验外科杂志,2019,36(12):2210-2213.
[10] 徐兰,吴宪鸣,熊美丽,等. 胸腔灌注榄香烯治疗腹膜透析合并胸腹瘘四例[J].中华肾脏病杂志,2020,36(1):55-57.
[11] 高树会,张桂彬,闫莉,等. 榄香烯联合洛铂对晚期非小细胞肺癌合并恶性胸腔积液的疗效观察[J].国际检验医学杂志,2023,44(15):1868-1872.
[12] 高树会,高海祥,闫莉,等. 榄香烯联合洛铂治疗晚期肺癌合并恶性胸腔积液的临床疗效[J].武警医学,2023,34(5):398-401.
[13] IWASAKI M, SHIMOMURA M, ISHIHARA S,et al.Surgical intervention for non-small-cell lung cancer with minimal malignant pleural effusion[J].Surg Today,2023, 53(6):655-662.

[1]	. [J]. JOURNAL OF CLINICAL RESEARCH, 2025, 42(9): 1667-1669.